Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Aspira Pathlab & Diagnostics Ltd (540788)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540788 NSE: Hospital & Healthcare Services | Small Cap | Aspira Pathlab&Diagn Share Price
₹136.52 6.50 (5.00%)
As on 28-Sep'26 16:59
Aspira Pathlab & Diagnostics Ltd (540788)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540788 NSE: Hospital & Healthcare Services | Small Cap | Aspira Pathlab&Diagn Share Price
₹136.52 6.50 (5.00%)
As on 28-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹141 Cr.
Current Price
₹136.5
52-Week Low / High
₹49 / 139
TTM EPS
₹2.3
TTM Sales
₹22.6 Cr.
Book Value per Share
₹12.3
P/E Ratio
58.57
Higher than its 5-year historical median
Industry PE
98.6
Price to Book (P/B)
11.12
Higher than its 5-year historical median
Price to Sales (P/S)
6.21
Higher than its 5-year historical median
EV/EBITDA
31.72
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
18.13%
Outperforms industry median
Return on Capital Employed (ROCE)
19.27%
Outperforms industry median
Return on Assets (ROA)
12.57%
Operating Profit Margin
16.2%
Net Profit Margin
9.19%
Gross Profit Margin
16.2%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
66.67%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
46.58%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹2 Cr.
Equity
₹10.3 Cr.
Face Value
₹10
All Time Low / High
₹14.15 / 138.99
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Aspira Pathlab & Diagnostics Ltd a good quality company?
Aspira Pathlab & Diagnostics Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Aspira Pathlab & Diagnostics Ltd performance compare with that of its Peers?
Revenue growth of Aspira Pathlab & Diagnostics Ltd vs industry peers?
Aspira Pathlab & Diagnostics Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Aspira Pathlab & Diagnostics Ltd?
Promoters hold 46.58% of the Aspira Pathlab & Diagnostics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Aspira Pathlab & Diagnostics Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 11.56% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Aspira Pathlab & Diagnostics Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 1.8% | -25.4% | -38.4% | -34.5% | -26.3% | 21.5% | 41.6% | 2.4% | -18.5% | 19.6% | - |
| Value Creation Index ⓘ | -0.9 | -2.8 | -3.7 | -3.5 | -2.9 | 0.5 | 2.0 | -0.8 | -2.3 | 0.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0.8 | 4.4 | 7.6 | 8.4 | 15.2 | 19.5 | 14.5 | 13.2 | 22 | 26 |
| Sales YoY Gr. | - | NA | 473.7% | 75.2% | 10.2% | 80.6% | 28.5% | -26% | -8.7% | 66.7% | - |
| Adj EPS ⓘ | 0.1 | -5.3 | -10.8 | -6.3 | -4.6 | 1.3 | 4.3 | -0.1 | -2.6 | 2 | -0.4 |
| YoY Gr. | - | -4475% | NA | NA | NA | NA | 223.1% | -102.1% | NA | NA | - |
| BVPS (₹) ⓘ | 16.2 | 11.4 | 0.6 | 6.3 | 4.1 | 8.1 | 12.4 | 12.4 | 9.9 | 11.9 | 11.9 |
| Adj Net Profit ⓘ | 0 | -2.7 | -5.6 | -5.2 | -4.2 | 1.4 | 4.5 | -0.1 | -2.7 | 2.1 | -0 |
| Cash Flow from Ops. ⓘ | -0.4 | -1.3 | -4.8 | -3.4 | -1.9 | 5.7 | 2 | -0 | 1.1 | 1.9 | - |
| Debt/CF from Ops. ⓘ | -7.2 | -5.7 | -2.4 | -2.2 | -4.2 | 0.2 | 0.4 | -80.2 | 1 | 0.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 21.2% | 4% | 66.7% | ||||
| Adj EPS ⓘ | 37% | NA | -22.2% | NA | ||||
| BVPSⓘ | -3.4% | 23.8% | -1.5% | 20.5% | ||||
| Share Price | - | 13.6% | 56.7% | 120.4% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.8 | -57 | -178.6 | -187.6 | -94.3 | 22.8 | 42.3 | -0.7 | -23.3 | 18.7 | -3.7 |
| Op. Profit Mgn % ⓘ | 0 | -339.5 | -88.9 | -42.5 | -21.7 | 23.1 | 32.3 | 11 | -9 | 16.2 | 3.8 |
| Net Profit Mgn % ⓘ | 0 | -359.1 | -128.1 | -67.9 | -50.4 | 9.1 | 22.8 | -0.6 | -20.2 | 9.5 | -1.8 |
| Debt to Equity ⓘ | 0.7 | 1.2 | 33.9 | 1.5 | 2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 0 | 1,188 | 353 | 244 | 224 | 89 | 91 | 175 | 187 | 127 | 35 |
| Cash Conv. Cycle ⓘ | 0 | 40 | 25 | 32 | 29 | 17 | 45 | 80 | 59 | 29 | 16 |
Valuation of Aspira Pathlab&Diagn - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'24 | Mar'25 |
|---|---|---|
| Sales | 13 | 22 |
| Operating Expenses ⓘ + | 14 | 18 |
| Operating Profit ⓘ | -1 | 4 |
| Operating Profit Margin (%) | -9.0% | 16.0% |
| Other Income ⓘ + | 0 | 0 |
| Interest ⓘ | 0 | 0 |
| Depreciation ⓘ | 2 | 1 |
| Profit Before Tax ⓘ | -3 | 2 |
| Tax ⓘ | 0 | 0 |
| Profit After Tax | -3 | 2 |
| PAT Margin (%) | -20.2% | 9.2% |
| Adjusted EPS (₹) | -2.6 | 2.0 |
| Dividend Payout Ratio (%) | 0% | 0% |
| PARTICULARS | Mar'24 | Mar'25 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 10 | 12 | |||||||||
| Debt + | 1 | 1 | |||||||||
| Minority Interest | 0 | 0 | |||||||||
| Trade Payables | 1 | 1 | |||||||||
| Others Liabilities ⓘ | 3 | 3 | |||||||||
| Total Liabilities ⓘ | 15 | 17 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 7 | 7 | |||||||||
| CWIP ⓘ | 0 | 0 | |||||||||
| Investments ⓘ | 0 | 0 | |||||||||
| Inventories | 0 | 1 | |||||||||
| Trade Receivables | 2 | 2 | |||||||||
| Cash Equivalents | 1 | 2 | |||||||||
| Others Assets ⓘ | 4 | 6 | |||||||||
| Total Assets ⓘ | 15 | 17 | |||||||||
| PARTICULARS | Mar'24 | Mar'25 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 1 | 2 |
| Cash Flow From Investing Activity ⓘ + | 0 | 0 |
| Cash Flow From Financing Activity ⓘ + | -1 | -1 |
| Net Cash Flow ⓘ | 0 | 1 |
| PARTICULARS | Mar'24 | Mar'25 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -26.34 | 18.13 | ||||||||
| ROCE (%) | -20.54 | 19.27 | ||||||||
| Asset Turnover Ratio | 0.9 | 1.37 | ||||||||
| PAT to CFO Conversion(x) | N/A | 1 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 62 | 38.10 | ||||||||
| Inventory Days | 12.40 | 8 | ||||||||
| Payable Days | 101.10 | 72.30 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Aspira Pathlab & Diagnostics Ltd FAQs
The current trading price of Aspira Pathlab&Diagn on 28-Sep-2026 16:59 is ₹136.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Sep-2026 the market cap of Aspira Pathlab&Diagn stood at ₹140.5 Cr
The latest P/E ratio of Aspira Pathlab&Diagn as of 27-Sep-2026 is 0.00.
The latest P/B ratio of Aspira Pathlab&Diagn as of 27-Sep-2026 is 11.52.
The 52-week high of Aspira Pathlab&Diagn is ₹139.0 and the 52-week low is ₹49.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aspira Pathlab&Diagn is ₹25.90 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Aspira Pathlab & Diagnostics Ltd is a below average quality company.
The key valuation ratios of Aspira Pathlab & Diagnostics Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aspira Pathlab & Diagnostics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Limited is a public limited company incorporated and domiciled in India. The company is engaged in the business of running, owning, managing and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai.
It has its registered office at Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai, Maharashtra, India.
The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company’s performance, allocate resources based on the analysis of the various performance indicator of the Company as a single unit.
Business area of the company
The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
